Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 4/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | ALDH3A1 | P30838 | 10/20 | 0.48 |
| ▸ | ALDH2 | P05091 | 4/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17830744 | 0.90 | ALDH1A1 (0.55) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL17830749 | 0.89 | CA1 (0.49) | CHRM5HSP90AA1CA1CA2CA9 | |
| SCHEMBL17830746 | 0.88 | ALDH1A1 (0.51) | CHRM5CA12CA1CA2CA9 | |
| SCHEMBL17830742 | 0.86 | ALDH1A1 (0.63) | HSP90AA1ALDH1A1ALDH3A1ALDH2 | |
| SCHEMBL17830751 | 0.86 | ALDH1A1 (0.51) | CHRM5CA12CA1CA2CA9 | |
| SCHEMBL17830710 | 0.85 | ALDH1A1 (0.64) | ALDH1A1ALDH3A1ALDH2 | |
| SCHEMBL17830740 | 0.84 | ALDH1A1 (0.52) | CHRM5CA12CA1CA2CA9 | |
| SCHEMBL17830745 | 0.82 | ALDH1A1 (0.56) | ALDH1A1ALDH3A1ALDH2 | |
| SCHEMBL17830753 | 0.82 | CA12 (0.51) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL30937987 | 0.81 | CHRM5 (0.76) | CHRM5HSP90AA1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943506-B2 | BCL6 inhibitors as anticancer agents | CORNELL UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-9943506-B2 | BCL6 inhibitors as anticancer agents | CORNELL UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | BCL6, BCL6B, BAZ2A | CHRM5 4879/4885HSP90AA1 1728/4885CA12 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.